Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient

Direct‐acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV‐HCV‐coinfected patients treated with DAAs. We repo...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 67; no. 2; pp. 791 - 793
Main Authors Vionnet, Julien, Pascual, Manuel, Testoni, Barbara, Combet, Christophe, Godat, Sébastien, Vijgen, Sandrine, Aubert, Vincent, Rubbia‐Brandt, Laura, Zoulim, Fabien, Moradpour, Darius
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.02.2018
Wiley-Blackwell
Subjects
Antiviral agents
Core protein
Hepatitis
Hepatitis B
Hepatitis B core antigen
Hepatitis C
Hepatology
Interferon
Life Sciences
Liver
Liver transplantation
Liver transplants
Microbiology and Parasitology
Transplantation
Transplants & implants
Virology
Online AccessGet full text

Cover

More Information
Summary:Direct‐acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV‐HCV‐coinfected patients treated with DAAs. We report on a case of late HBV reactivation after DAA‐based treatment of recurrent hepatitis C in an antibody against hepatitis B core antigen (anti‐HBc)‐positive LT recipient. (Hepatology 2018;67:791‐793).
Bibliography:Potential conflict of interest: Nothing to report.
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0270-9139
1527-3350
DOI:10.1002/hep.29528